Advanced search
Publication Cover
OncoImmunology Volume 7, 2018 - Issue 7
Submit an article Journal homepage
2,254
Views
56
CrossRef citations to date
0
Altmetric
Original Research

Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma

Kirtesh R. PatelDepartment of Therapeutic Radiology, Smilow Cancer Center, Yale University School of Medicine, New Haven, CT, USACorrespondence[email protected]
, MD,
Anthony MartinezDeparment of Pathology, Emory University School of Medicine, Atlanta, GA, USA
, MD,
John M. StahlDepartment of Therapeutic Radiology, Smilow Cancer Center, Yale University School of Medicine, New Haven, CT, USA
, MD,
Suzanna J. LoganDeparment of Pathology, Emory University School of Medicine, Atlanta, GA, USA
, MD, PhD,
Adam J. PerriconeDeparment of Pathology, Emory University School of Medicine, Atlanta, GA, USA
, MD PhD,
Matthew J. FerrisDepartment of Radiation Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA
, MD,
Zachary S. BuchwaldDepartment of Radiation Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA
, MD, PhD,
Mudit ChowdharyDepartment of Radiation Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USACorrespondence[email protected]
, MD,
Keith A. DelmanDivision of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA
, MD,
David K. MonsonDivision of Orthopaedic Oncology, Department of Orthopedic Surgery, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA
, MD,
Shervin V. OskoueiDivision of Orthopaedic Oncology, Department of Orthopedic Surgery, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA
, MD,
Nicholas B. ReimerDivision of Orthopaedic Oncology, Department of Orthopedic Surgery, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA
, MD,
Kenneth CardonaDivision of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA
, MD,
Mark A. EdgarDeparment of Pathology, Emory University School of Medicine, Atlanta, GA, USA
, MD &
Karen D. GodetteDepartment of Radiation Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA
, MD show all
Article: e1442168 | Received 29 Jan 2018, Accepted 14 Feb 2018, Published online: 15 Mar 2018

Citations (56)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Jiaqiang Wang, Hong Ge & Zhichao Tian. (2023) Immunotherapy Plus Radiotherapy for the Treatment of Sarcomas: Is There a Potential for Synergism?. OncoTargets and Therapy 16, pages 385-397.
Read now
Robby Barnestein, Loïck Galland, Laura Kalfeist, François Ghiringhelli, Sylvain Ladoire & Emeric Limagne. (2022) Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness. OncoImmunology 11:1.
Read now
Giacomo G Baldi, Alessandro Gronchi, Marcella Tazzari & Silvia Stacchiotti. (2022) Immunotherapy in soft tissue sarcoma: current evidence and future perspectives in a variegated family of different tumor. Expert Review of Anticancer Therapy 22:5, pages 491-503.
Read now
D. Evrard, M. Hourseau, A. Couvelard, V. Paradis, H. Gauthier, E. Raymond, C. Halimi, B. Barry & S. Faivre. (2020) PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma. OncoImmunology 9:1.
Read now
Wenli Zuo & Lingdi Zhao. (2019) Recent advances and application of PD-1 blockade in sarcoma. OncoTargets and Therapy 12, pages 6887-6896.
Read now

Articles from other publishers (51)

Xuelian Wang, Ping Wang, Xiang Huang, Yanan Zhang & Pei Zhang. (2023) Biomarker für die Immuntherapie bei Speiseröhrenkrebs. Kompass Onkologie, pages 1-5.
Crossref
Ryan P. Coll, Scott J. Bright, David K.J. Martinus, Dimitra K. Georgiou, Gabriel O. Sawakuchi & H. Charles Manning. (2023) Alpha Particle–Emitting Radiopharmaceuticals as Cancer Therapy: Biological Basis, Current Status, and Future Outlook for Therapeutics Discovery. Molecular Imaging and Biology.
Crossref
Chin Sern Yiong, Tzu Ping Lin, Vivian Yujing Lim, Tan Boon Toh & Valerie Shiwen Yang. (2023) Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation?. Biomarker Research 11:1.
Crossref
Görkem Yazıcı Şener, Osman Sütcüoğlu, Betül Öğüt, Deniz Can Güven, Altan Kavuncuoğlu, Nuriye Özdemir, Ahmet Özet, Sercan Aksoy, Yeşim Gaye Güler Tezel, Nalan Akyürek & Ozan Yazıcı. (2023) Comparison of PD-L1 and VISTA expression status in primary and recurrent/refractory tissue after (chemo)radiotherapy in head and neck cancer. Strahlentherapie und Onkologie 199:8, pages 761-772.
Crossref
Xuelian Wang, Ping Wang, Xiang Huang, Yanan Han & Pei Zhang. (2023) Biomarkers for immunotherapy in esophageal cancer. Frontiers in Immunology 14.
Crossref
Shoaib Bashir, Lei Wen, Ping Zhang, Minting Ye, Yin Li, Weiping Hong, Junjie Zhen, Mingyao Lai, Hui Wang, Yanying Yang, Xingrui Chen, Rishun Luo, Guoxia Jia, Yao Guo, Linbo Cai & Meng Xu. (2023) Efficacy and safety of combined immunotherapy and stereotactic radiosurgery in NSCLCBM patients and a novel prognostic nomogram: A real-world study. Frontiers in Oncology 13.
Crossref
Pouya Dehghankelishadi, Parisa Badiee, Michelle F. Maritz, Nicole Dmochowska & Benjamin Thierry. (2023) Bosutinib high density lipoprotein nanoformulation has potent tumour radiosensitisation effects. Journal of Nanobiotechnology 21:1.
Crossref
Hao Zhang, Lin Liu, Jinbo Liu, Pengyuan Dang, Shengyun Hu, Weitang Yuan, Zhenqiang Sun, Yang Liu & Chengzeng Wang. (2023) Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers. Molecular Cancer 22:1.
Crossref
Haonan Li, Qiang Luo, Hu Zhang, Xuelei Ma, Zhongwei Gu, Qiyong Gong & Kui Luo. (2023) Nanomedicine embraces cancer radio-immunotherapy: mechanism, design, recent advances, and clinical translation. Chemical Society Reviews 52:1, pages 47-96.
Crossref
Teodora Alexa-Stratulat, Mihai Vasile Marinca, Ioana-Dana Alexa & Sabina Antonela Antoniu. 2023.
Nam P. Nguyen, Ahmed Ali, Vincent Vinh-Hung, Olena Gorobets, Alexander Chi, Thandeka Mazibuko, Natália Migliore, Maria Vasileiou, David Lehrman, Mohammad Mohammadianpanah, Seyed Alireza Javadinia, Gokoulakrichenane Loganadane, Trinanjan Basu, Satya Bose, Ulf Karlsson & Huan Giap. (2022) Stereotactic Body Radiotherapy and Immunotherapy for Older Patients with Oligometastases: A Proposed Paradigm by the International Geriatric Radiotherapy Group. Cancers 15:1, pages 244.
Crossref
Tiziana Feola, Francesca Carbonara, Monica Verrico, Rosa Maria Di Crescenzo, Francesca Gianno, Claudio Colonnese, Antonietta Arcella, Dario de Alcubierre, Silverio Tomao, Vincenzo Esposito, Felice Giangaspero, Giuseppe Minniti & Marie-Lise Jaffrain-Rea. (2022) Immunotherapy for Aggressive and Metastatic Pituitary Neuroendocrine Tumors (PitNETs): State-of-the Art. Cancers 14:17, pages 4093.
Crossref
Junlei Zhang, Sijie Wang, Xuemeng Guo, Yichao Lu, Xu Liu, Mengshi Jiang, Xiang Li, Bing Qin, Zhenyu Luo, Huihui Liu, Qingpo Li, Yong-Zhong Du, Lihua Luo & Jian You. (2022) Arginine Supplementation Targeting Tumor-Killing Immune Cells Reconstructs the Tumor Microenvironment and Enhances the Antitumor Immune Response. ACS Nano 16:8, pages 12964-12978.
Crossref
Olga Kuczkiewicz-Siemion, Kamil Sokół, Beata Puton, Aneta Borkowska & Anna Szumera-Ciećkiewicz. (2022) The Role of Pathology-Based Methods in Qualitative and Quantitative Approaches to Cancer Immunotherapy. Cancers 14:15, pages 3833.
Crossref
Kazuhiko Hashimoto, Shunji Nishimura, Tomohiko Ito, Ryosuke Kakinoki & Masao Akagi. (2022) Immunohistochemical expression and clinicopathological assessment of PD-1, PD-L1, NY-ESO-1, and MAGE-A4 expression in highly aggressive soft tissue sarcomas. European Journal of Histochemistry 66:2.
Crossref
Peter H. Goff, Laura Riolobos, Bonnie J. LaFleur, Matthew B. Spraker, Y. David Seo, Kimberly S. Smythe, Jean S. Campbell, Robert H. Pierce, Yuzheng ZhangQianchuan HeEdward Y. Kim, Stephanie K. Schaub, Gabrielle M. Kane, Jose G. Mantilla, Eleanor Y. Chen, Robert Ricciotti, Matthew J. Thompson, Lee D. CranmerMichael J. WagnerElizabeth T. Loggers, Robin L. Jones, Erin MurphyWendy M. BlumenscheinTerrill K. McClanahanJon EarlsKevin C. FlanaganNatalie A. LaFranzoTeresa S. Kim & Seth M. Pollack. (2022) Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells. Clinical Cancer Research 28:8, pages 1701-1711.
Crossref
Matthieu Roulleaux Dugage, Elise F. Nassif, Antoine Italiano & Rastislav Bahleda. (2021) Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review. Frontiers in Immunology 12.
Crossref
Ottavia Clemente, Alessandro Ottaiano, Giuseppe Di Lorenzo, Alessandra Bracigliano, Sabrina Lamia, Lucia Cannella, Antonio Pizzolorusso, Massimiliano Di Marzo, Mariachiara Santorsola, Annarosaria De Chiara, Flavio Fazioli & Salvatore Tafuto. (2021) Is immunotherapy in the future of therapeutic management of sarcomas?. Journal of Translational Medicine 19:1.
Crossref
Yaolin Chen, Xiangzhen Liu, Jijun Liu, Donghua Liang, Mingdong Zhao, Weiguang Yu & Pengfei Chen. (2021) Nivolumab plus ipilimumab versus nivolumab in individuals with treatment-naive programmed death-ligand 1 positive metastatic soft tissue sarcomas: a multicentre retrospective study. BMC Cancer 21:1.
Crossref
Fan Tang, Yan Tie, Yu-Quan Wei, Chong-Qi Tu & Xia-Wei Wei. (2021) Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1876:2, pages 188606.
Crossref
Christopher R. Cunningham, Leslie Dodd, Magda Esebua & Lester J. Layfield. (2021) PD-L1 expression in sarcomas: An immunohistochemical study and review of the literature. Annals of Diagnostic Pathology 55, pages 151823.
Crossref
Takuya Kumazawa, Yasumasa Mori, Hiro Sato, Tiara Permata, Yuki Uchihara, Shin-Ei Noda, Kohei Okada, Sangeeta Kakoti, Keiji Suzuki, Hayato Ikota, Hideaki Yokoo, Soehartati Gondhowiardjo, Takashi Nakano, Tatsuya Ohno & Atsushi Shibata. (2021) Expression of non‑homologous end joining factor, Ku80, is negatively correlated with PD‑L1 expression in cancer cells after X‑ray irradiation. Oncology Letters 23:1.
Crossref
Min Kyu Kang, Shin Yup Lee, Jin Eun Choi, Sook Kyung Do, Moon‐June Cho, Jun‐Sang Kim & Jae Yong Park. (2021) Prognostic implication of PD‐L1 polymorphisms in non‐small cell lung cancer treated with radiotherapy . Cancer Medicine 10:22, pages 8071-8078.
Crossref
Mohamed Kelany, Thomas FE. Barth, Dina Salem & Marwa M. Shakweer. (2021) Prevalence and Prognostic Implications of PD-L1 Expression in Soft Tissue Sarcomas. Pathology and Oncology Research 27.
Crossref
Vitaly Margulis, Yuval Freifeld, Laurentiu M. Pop, Subrata Manna, Payal Kapur, Ivan Pedrosa, Alana Christie, Osama Mohamad, Samantha Mannala, Nirmish Singla, Michael Wait, Aditya Bagrodia, Solomon L. Woldu, Jeffrey Gahan, James Brugarolas, Robert Timmerman & Raquibul Hannan. (2021) Neoadjuvant SABR for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombus—Safety Lead-in Results of a Phase 2 Trial. International Journal of Radiation Oncology*Biology*Physics 110:4, pages 1135-1142.
Crossref
Serena Pillozzi, Andrea Bernini, Ilaria Palchetti, Olivia Crociani, Lorenzo Antonuzzo, Domenico Campanacci & Guido Scoccianti. (2021) Soft Tissue Sarcoma: An Insight on Biomarkers at Molecular, Metabolic and Cellular Level. Cancers 13:12, pages 3044.
Crossref
Xiang Li, Lihua Luo, Mengshi Jiang, Chunqi Zhu, Yingying Shi, Junlei Zhang, Bing Qin, Zhenyu Luo, Xuemeng Guo, Yichao Lu, Xinyu Shan, Yu Liu, Yongzhong Du, Peng Ling & Jian You. (2021) Cocktail strategy for ‘cold’ tumors therapy via active recruitment of CD8+ T cells and enhancing their function. Journal of Controlled Release 334, pages 413-426.
Crossref
Tahlia Scheinberg, Anna Lomax, Martin Tattersall, David Thomas, Geoff McCowage, Michael Sullivan, Rooshdiya Karim, Peter P. Luk, Annabelle Mahar, Fiona Bonar & Vivek A. Bhadri. (2020) PD ‐1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma . Cancer Reports 4:2.
Crossref
Mark A. DamanteKristin M. HuntoonJoshua D. PalmerDavid A. LiebnerJames Bradley Elder. (2021) A case of multiple synchronously diagnosed brain metastases from alveolar soft part sarcoma without concurrent lung involvement. Surgical Neurology International 12, pages 111.
Crossref
Minsu Kwon, Hanul Jung, Gi-Hoon Nam & In-San Kim. (2021) The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy. Journal of Controlled Release 331, pages 321-334.
Crossref
Hayden Snow, Catherine Mitchell, Shona Hendry, Madeleine McKinley, David Byrne, Sam Ngan, Sarat Chander, Julie Chu, Jayesh Desai, Susie Bae, Michael Henderson, Peter Choong & David Gyorki. (2020) Characterising the immune microenvironment in liposarcoma, its impact on prognosis and the impact of radiotherapy. Journal of Surgical Oncology 123:1, pages 117-126.
Crossref
Xiao-Jiang Chen, Shu-Qiang Yuan, Jin-Ling Duan, Yong-Ming Chen, Shi Chen, Yun Wang & Yuan-Fang Li. (2020) The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis. Disease Markers 2020, pages 1-14.
Crossref
Alexander Philipovskiy, Karinn Chambers, Ioannis Konstantinidis, Richard McCallum, Javier Corral & Sumit Gaur. (2020) Remarkable response to combined immunochemotherapy in patients with metastatic triple-negative breast cancer. Immunotherapy 12:18, pages 1293-1302.
Crossref
Madyson Colton, Eleanor J. Cheadle, Jamie Honeychurch & Tim M. Illidge. (2020) Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy combinations. Radiation Oncology 15:1.
Crossref
Benjamin Chevalier, David Pasquier, Eric Felix Lartigau, Cyrus Chargari, Antoine Schernberg, Arnaud Jannin, Xavier Mirabel, Marie-Christine Vantyghem & Alexandre Escande. (2020) Metformin: (future) best friend of the radiation oncologist?. Radiotherapy and Oncology 151, pages 95-105.
Crossref
Valentine Suteau, Alexandre Collin, Philippe Menei, Patrice Rodien, Marie-Christine Rousselet & Claire Briet. (2020) Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor. Cancer Immunology, Immunotherapy 69:10, pages 2053-2061.
Crossref
Jessica Bridoux, Katrijn Broos, Quentin Lecocq, Pieterjan Debie, Charlotte Martin, Steven Ballet, Geert Raes, Sara Neyt, Christian Vanhove, Karine Breckpot, Nick Devoogdt, Vicky Caveliers, Marleen Keyaerts & Catarina Xavier. (2020) Anti-Human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation. Biomolecules 10:10, pages 1388.
Crossref
Lingzhi Hong, Marcelo V. Negrao, Seyedeh S. Dibaj, Runzhe Chen, Alexandre Reuben, Jadi M. Bohac, Xiaoke Liu, Ferdinandos Skoulidis, Carl M. Gay, Tina Cascone, Kyle G. Mitchell, Hai T. Tran, Xiuning Le, Lauren A. Byers, Boris Sepesi, Mehmet Altan, Yasir Y. Elamin, Frank V. Fossella, Jonathan M. Kurie, Charles Lu, Frank E. Mott, Anne S. Tsao, Waree Rinsurongkawong, Jeff Lewis, Don L. Gibbons, Bonnie S. Glisson, George R. BlumenscheinJr.Jr., Emily B. Roarty, P. Andrew Futreal, Ignacio I. Wistuba, Jack A. Roth, Stephen G. Swisher, Vassiliki A. Papadimitrakopoulou, John V. Heymach, J. Jack Lee, George R. Simon & Jianjun Zhang. (2020) Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. Journal of Thoracic Oncology 15:9, pages 1449-1459.
Crossref
Takeharu Ono, Koichi Azuma, Akihiko Kawahara, Tatsuyuki Kakuma, Fumihiko Sato, Toshihiko Kawaguchi, Jun Akiba & Hirohito Umeno. (2020) Changes in immune parameters between pre-treatment and recurrence after (chemo) radiation therapy in patients with head and neck cancer. Scientific Reports 10:1.
Crossref
Feng Wang, Tao Yu, Chengbin Ma, Hongmou Yuan, Haifei Zhang & Zhiyu Zhang. (2020) Prognostic Value of Programmed Cell Death 1 Ligand-1 in Patients With Bone and Soft Tissue Sarcomas: A Systemic and Comprehensive Meta-Analysis Based on 3,680 Patients. Frontiers in Oncology 10.
Crossref
Hiro Sato, Noriyuki Okonogi & Takashi Nakano. (2020) Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment. International Journal of Clinical Oncology 25:5, pages 801-809.
Crossref
Ana Cristina Vargas, Fiona M. Maclean, Loretta Sioson, Dinh Tran, Fiona Bonar, Annabelle Mahar, Alison L. Cheah, Peter Russell, Peter Grimison, Louise Richardson & Anthony J. Gill. (2020) Prevalence of PD-L1 expression in matched recurrent and/or metastatic sarcoma samples and in a range of selected sarcomas subtypes. PLOS ONE 15:4, pages e0222551.
Crossref
Antonella Borgatti, Erin B. Dickerson & Jessica Lawrence. (2019) Emerging therapeutic approaches for canine sarcomas: Pushing the boundaries beyond the conventional. Veterinary and Comparative Oncology 18:1, pages 9-24.
Crossref
Moito Iijima, Noriyuki Okonogi, Nakako Izumi Nakajima, Yukie Morokoshi, Hiroaki Kanda, Taiju Yamada, Yusuke Kobayashi, Kouji Banno, Masaru Wakatsuki, Shigeru Yamada, Tadashi Kamada, Daisuke Aoki & Sumitaka Hasegawa. (2020) Significance of PD-L1 expression in carbon-ion radiotherapy for uterine cervical adeno/adenosquamous carcinoma. Journal of Gynecologic Oncology 31:2.
Crossref
Àngela Maria Bellmunt, Laura López-Puerto, Juan Lorente & Daniel Closa. (2019) Involvement of extracellular vesicles in the macrophage-tumor cell communication in head and neck squamous cell carcinoma. PLOS ONE 14:11, pages e0224710.
Crossref
Liping Huang, Yanan Li, Yunai Du, Yiyi Zhang, Xiuxia Wang, Yuan Ding, Xiangliang Yang, Fanling Meng, Jiasheng Tu, Liang Luo & Chunmeng Sun. (2019) Mild photothermal therapy potentiates anti-PD-L1 treatment for immunologically cold tumors via an all-in-one and all-in-control strategy. Nature Communications 10:1.
Crossref
Fengpeng Wu, Jun Wang, Congrong Yang, Chaoxi Zhou, Wenbo Niu, Jianfeng Zhang, Guanglin Wang, Yafan Yang & Guiying Wang. (2019) Volumetric imaging parameters are significant for predicting the pathological complete response of preoperative concurrent chemoradiotherapy in local advanced rectal cancer. Journal of Radiation Research 60:5, pages 666-676.
Crossref
James E. Bates, Christopher G. Morris, Michael T. Milano, Anamaria R. Yeung & Bradford S. Hoppe. (2019) Immunotherapy with hypofractionated radiotherapy in metastatic non-small cell lung cancer: An analysis of the National Cancer Database. Radiotherapy and Oncology 138, pages 75-79.
Crossref
Xiangfeng Shen, Lihong Zhang, Jicheng Li, Yulin Li, Yishu Wang & Zhi-Xiang Xu. (2019) Recent Findings in the Regulation of Programmed Death Ligand 1 Expression. Frontiers in Immunology 10.
Crossref
Maria Protopapa, Vassilis Kouloulias, Styliani Nikoloudi, Christos Papadimitriou, Giannis Gogalis & Anna Zygogianni. (2019) From Whole-Brain Radiotherapy to Immunotherapy: A Multidisciplinary Approach for Patients with Brain Metastases from NSCLC. Journal of Oncology 2019, pages 1-12.
Crossref
S. Peters, U. Dafni, M. Boyer, D. De Ruysscher, C. Faivre-Finn, E. Felip, P. Garrido, N. Girard, M. Guckenberger, J. Haanen, C. Le Pechoux, F. Mornex, M. Ozsahin, L. Paz-Ares, D. Planchard, D. Raben, S. Ramalingam, M. Reck, E. Smit, R. Stahel, A. Stenzinger, C. Swanton, S. Vallone & M.C. Garassino. (2019) Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Annals of Oncology 30:2, pages 161-165.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.